Topical clobetasol propionate treatment and cutaneous adverse effects in patients with early-stage mycosis fungoides: An observational study Journal Article
| Authors: | Geller, S.; Myskowski, P. L. |
| Article Title: | Topical clobetasol propionate treatment and cutaneous adverse effects in patients with early-stage mycosis fungoides: An observational study |
| Abstract: | Topical superpotent class I corticosteroids (CSs) are highly effective in the treatment of early-stage mycosis fungoides (MF) and are readily available, easily applied, and have minor side effects compared to other topical therapeutic options. Because MF is a chronic disease, prolonged treatment is needed, raising the concern of CS-induced cutaneous adverse effects (AEs). In this observational study, we aimed to evaluate the risk for skin AEs of clobetasol propionate cream 0.05% in patients with early-stage MF. Thirteen consecutive patients with MF were treated with clobetasol propionate cream 0.05% once or twice daily as monotherapy and were followed for 4 to 17 months. One participant was lost to follow-up, and the remaining 12 participants responded to treatment with topical clobetasol propionate with minimal side effects. With proper education and monitoring, topical CSs are a safe and effective mainstay of treatment for patches and flat plaques in patients with early-stage localized MF. |
| Journal Title: | Cutis |
| Volume: | 105 |
| Issue: | 5 |
| ISSN: | 0011-4162 |
| Publisher: | Frontline Medical Communications, Inc. |
| Date Published: | 2020-05-01 |
| Start Page: | E27 |
| End Page: | E32 |
| Language: | English |
| PUBMED: | 32603400 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 August 2020 -- Source: Scopus |
Citation Impact
Related MSK Work